- ICH GCP
- 米国臨床試験登録
- 臨床試験 NCT07053384
- オリジナルトライアル
Fostemsavir(FTR)の有無にかかわらずVH3810109の使用を調査するための研究 (ENTRANCE)
HIV-1と一緒に生息する成人のウイルス貯留層のウイルス貯留層におけるインテグラゼ阻害剤ベースの抗レトロウイルス療法と組み合わせて、経口フォステムサビルとの有無にかかわらず、静脈内VH3810109の投与の影響を調査するための探索第一相1B、多施設、無作為化、無盲検研究
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Bakersfield、California、アメリカ、93309
- GSK Investigational Site
-
San Diego、California、アメリカ、92103
- GSK Investigational Site
-
-
Florida
-
Ft. Pierce、Florida、アメリカ、34982-7148
- GSK Investigational Site
-
Orlando、Florida、アメリカ、32803-1851
- GSK Investigational Site
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- GSK Investigational Site
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- GSK Investigational Site
-
St Louis、Missouri、アメリカ、63110
- GSK Investigational Site
-
-
New York
-
New York、New York、アメリカ、10032
- GSK Investigational Site
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- GSK Investigational Site
-
Pittsburgh、Pennsylvania、アメリカ、15213
- GSK Investigational Site
-
-
Texas
-
Dallas、Texas、アメリカ、75246-2004
- GSK Investigational Site
-
Dallas、Texas、アメリカ、75208-4599
- GSK Investigational Site
-
-
-
-
-
London、イギリス、SE1 7EH
- GSK Investigational Site
-
London、イギリス、NW3 2QG
- GSK Investigational Site
-
London、イギリス、W2 1NY
- GSK Investigational Site
-
-
-
-
-
Rotterdam、オランダ、3015 GD
- GSK Investigational Site
-
-
-
-
-
Barcelona、スペイン、08036
- GSK Investigational Site
-
Barcelona、スペイン、08035
- GSK Investigational Site
-
Barcelona、スペイン、08003
- GSK Investigational Site
-
Barcelona、スペイン、8907
- GSK Investigational Site
-
Barcelona、スペイン、08026
- GSK Investigational Site
-
Barcelona、スペイン、08916
- GSK Investigational Site
-
Córdoba、スペイン、14004
- GSK Investigational Site
-
La Laguna Santa Cruz、スペイン、38320
- GSK Investigational Site
-
Madrid、スペイン、28041
- GSK Investigational Site
-
Madrid、スペイン、28040
- GSK Investigational Site
-
Madrid、スペイン、28046
- GSK Investigational Site
-
Madrid、スペイン、28034
- GSK Investigational Site
-
Madrid、スペイン、28031
- GSK Investigational Site
-
Madrid、スペイン、28020
- GSK Investigational Site
-
Palma de Mallorca、スペイン、07120
- GSK Investigational Site
-
Palma de Mallorca、スペイン、7198
- GSK Investigational Site
-
Seville、スペイン、41013
- GSK Investigational Site
-
Valencia、スペイン、46026
- GSK Investigational Site
-
Valencia、スペイン、46014
- GSK Investigational Site
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、スペイン、28224
- GSK Investigational Site
-
-
-
-
Capital Region
-
Hvidovre、Capital Region、デンマーク、2650
- GSK Investigational Site
-
-
Central Jutland
-
Aarhus N、Central Jutland、デンマーク、8200
- GSK Investigational Site
-
-
-
-
-
Brussels、ベルギー、1000
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、ベルギー、9000
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
AGE
• Age between 18 years and 70 years old at the time of obtaining informed consent.
SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.
PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of HIV-1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.
Population 1 only:
- Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
- CD4+ T cell count >=300 cells/microliter (μL) at Screening.
- Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.
Population 2 only:
- Participant is stably virologically suppressed (plasma HIV-1 RNA <50 c/mL).
- Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
- CD4+ T cell count >=450 cells/μL at Screening.
WEIGHT
• Body weight >=50 kg to <=115 kg.
INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.
Exclusion Criteria:
CONCURRENT MEDICAL CONDITIONS & MEDICAL HISTORY
- Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
- Participant has documented diagnosis of HIV-2 infection.
- Participant is known to have acquired HIV via perinatal transmission.
- Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
- Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
- Ongoing or clinically relevant pancreatitis.
- Current HIV-related kidney disease.
- History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.
CARDIAC & CARDIOVASCULAR CONDITIONS
- Participants who are at clinically significant risk of cardiovascular disease.
- Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
- Confirmed QTcF value outside normal range at Screening or Day 1.
HEPATIC CONDITIONS
- History of clinically relevant hepatitis in the 6 months prior to Screening.
- Participants with severe hepatic impairment.
- Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
- Unstable liver disease.
- History of liver cirrhosis with or without hepatitis viral co-infection.
NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.
LABORATORY DIAGNOSTIC ASSESSMENTS
- Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
- Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
- Alanine transferase (ALT) >=3 times the upper limit of normal (ULN) at Screening.
- Estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m^2.
- Hemoglobin >=Grade 2 at Screening.
- Platelets >=Grade 2 at Screening.
- Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
- Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.
Population 2 only:
• Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.
INFECTIOUS DISEASES
- Active hepatitis B virus (HBV) co-infection.
- Active hepatitis C virus (HCV) co-infection.
- Participant has untreated syphilis before enrolment.
- Known history of active Mycobacterium TB disease (regardless of treatment status).
ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.
PRIOR AND CONCOMITANT MEDICATIONS
-
Prior use of any of the following agents:
- long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])
- FTR (any lifetime use)
- HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)
- HIV-1 monoclonal antibody therapy (any lifetime use).
-
Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
-
History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
-
Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
-
Treatment with any of the following agents within 30 days of enrolment:
- radiation therapy
- cytotoxic chemotherapeutic agents
- anti-tuberculosis therapy
- immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
-
Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.
Population 1 only:
• Known use of PrEP or PEP within <30 days (for oral agents) or <52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.
Population 2 only:
• Current use of NNRTI-containing ART.
OTHER EXCLUSIONS
- History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
- Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
- Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Participant is currently participating in, or anticipates being selected for, any other interventional study.
- Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. |
|
実験的:Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
他の名前:
|
|
実験的:Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
他の名前:
Fostemsavir will be administered.
他の名前:
|
|
実験的:Participants receiving VH3810109 in ATI Phase (Step 2)
|
VH3810109 will be administered.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells
時間枠:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells
時間枠:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells
時間枠:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count
時間枠:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count
時間枠:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)
時間枠:From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention
時間枠:From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
ATI Phase (Step 2): Time to ART restart
時間枠:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs
時間枠:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with SAEs and deaths
時間枠:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)
時間枠:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 221794
- 2025-520629-19-00 (その他の識別子:EU CT Number)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
IPD 共有時間枠
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共有アクセス基準
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。